glp-1 als Neurologists warn drugs may speed decline GLP-1 Receptor Agonists in Solid

Journal of Basic and Clinical Physiology and Pharmacology, 31(4), 20190206

Currently, the clinical treatment of OA still faces major challenges, and the existing strategy is mainly end-stage arthroplasty, which has the disadvantages of biomechanical mismatch, risk of long-term loosening, and incomplete functional recovery, leaving patients with long-term pain and economic burden[3, 4]

doi: 10.1016/j.cca.2019.12.009 23

By January 2024, monthly Medicaid spending on Wegovy alone exceeded $51 million, and by October 2024, it had grown to $192 million

Weight loss effectiveness: what the clinical trials show Numbers matter more than marketing

And hosted several GLP-1 meetups, different spaces, same energy